MedTrace Logo

Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

NCT00496847 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-12-16

No results posted yet for this study

Summary

PERIOGEN, containing rhPDGF and -beta-TCP, promotes gingival healing and corrects periodontal defects. This study will test the safety and efficacy of PERIOGEN in the treatment of periodontal disease

Conditions

  • Intrabony Periodontal Defect

Interventions

DRUG

PERIOGEN

Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)

DRUG

Beta TCP alone

Implantation of β-TCP (0.5 g) alone

Sponsors & Collaborators

  • Virchow Group

    lead INDUSTRY

Principal Investigators

  • A Jayakumar, MDS · Sri Sai Dental college of surgery, Vikarabad, RR Dist, AP, India.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-08-31
Completion
2009-08-31

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00496847 on ClinicalTrials.gov